Preview

Epilepsia and paroxyzmal conditions

Advanced search

Resolution of the Expert Forum on the use of perampanel in routine clinical practice in Russia

Full Text:

Abstract

.

About the Author

article Editorial

Russian Federation


References

1. World Health Organization. Atlas: epilepsy care in the world. Geneva: World Health Organization; 2005.

2. Guekht A., Hauser W. A., Milchakova L., Churillin Y., Shpak A., Gusev E. The epidemiology of epilepsy in the Russian Federation. Epilepsy Res. 2010; 92 (2-3): 209-18.

3. Avakyan G. N., Voronina T. A., Hromyh E. A. Epilepsy. Pathogenesis. Pathogenetic therapy. Manual for doctors [Epilepsii. Patogenez. Patogeneticheskaya terapiya. Posobie dlya vrachey (in russian)]. Moscow. 2007; 148 s.

4. Brodie M. J., Barry S. J., Bamagous G. A., Norrie J. D., Kwan P. Patterns of treatment response in newly diagnosed epilepsy. Neurology. 2012 May 15; 78 (20): 1548-54.

5. Instruktsiya po meditsinskomu primeneniyu preparata perampanel RU LS- LP-002200.

6. French J. A., Krauss G. L., Biton V. et al. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology. 2012; 79: 589-96.

7. French J. A., Krauss G. L., Steinhoff B. J., et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia. 2013; 54: 117-25.

8. Krauss G. L., Serratosa J. M., Villanueva V. et al. Randomized phase III study 306: adjunctive perampanel for refractory partialonset seizures. Neurology. 2012; 78: 1408-15.

9. Krauss G. L., Perucca E., Ben-Menachem E. et al. Long-term safety of perampanel and seizure outcomes in refractory partialonset seizures and secondarily generalized seizures: results from phase III extension study 307. Epilepsia. 2014; 55: 1058-68.

10. Krauss G. L., Perucca E., Kwan P. et al. Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307. Epilepsia. 2018; 59: 866-876.

11. French J. A., Krauss G. L., Wechsler R. T. et al. Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy a randomized trial. Neurology. 2015; 85: 950-7.

12. O’Brien T.J., Steinhoff B. J., Laurenza A. et al. Myoclonic and absence seizures in patients with idiopathic generalized epilepsy (IGE): exploratory outcomes in a phase III PGTC study with adjunctive perampanel. European Congress on Epileptology 2016: Abstract #0073.

13. Rohracher A., Zimmermann G., Villanueva V. et al. Perampanel in routine clinical use across Europe: Pooled, multicenter, observational data. Epilepsia. 2018; 1-13.

14. Karlov V. A., Belyaev O. V., Vlasov P. N. et al. Nevrologiya, neyropsihiatriya, psihosomatika (in Russian). 2016; (spetsvypusk 1): 11-17.

15. Chong D. J., Lerman A. M. Practice update: review of anticonvulsant therapy. Curr Neurol Neurosci Rep. 2016; 16 (4): 39.

16. EURAP: An International Antiepileptic Drugs and Pregnancy Registry Interim Report – November 2017.

17. Vazquez B., Dobrinsky C., Yang H. et al. Review of pregnancy events in perampanel clinical studies.

18. Perunova N. Yu., Danilova S. A., Sorokova E. V., Safonov A. G., Chaschina O. N. Epidemiological study of epilepsy in adolescents in Yekaterinburg. 1-st All-Russian Congress “Modern Technologies in Pediatrics and Children’s Surgery (collection of materials) [Epidemiologicheskoe issledovanie epilepsii u podrostkov v Ekaterinburge. 1-y Vserossiyskiy kongress «Sovremennye tekhnologii v pediatrii i detskoy hirurgii (sbornik materialov) (in Russian)]. Moscow. 2002; 143-144.

19. Rosenfeld W., Conry J., Lagae L., Rozentals G., Yang H., Fain R., Williams B., Kumar D., Zhu J., Laurenza A. Efficacy and safety of perampanel in adolescent patients with drug-resistant partial seizures in three double-blind, placebo-controlled, phase III randomized clinical studies and a combined extension study. European Journal of Paediatric Neurology. 2015; 19: 435-445.

20. Steinhoff B. J., O’Brien T.J., Yang H., Laurenza A., Patten A., Bibbiani F. Efficacy of adjunctive perampanel in adiopatic generalized epilepsy patients with drug-resistant primary generalized tonic-clonic seizures by age, sex and race: double-blind placebo-controlled phase III trial. European Journal of Neurology. 2015; 22 (1): 21-117. Abstr. O2112.

21. Piña-Garza J.E., Lagae L., Villanueva V. et al. Long-term effects of adjunctive perampanel on cognition in adolescents with partial seizures. Epilepsy & Behavior. 2018; 83: 50-58.

22. Heung Dong Kim, Ching-Shiang Chi, Tayard Desudchit, Marina Nikanorova, Anannit Visudtibhan, Charcrin Nabangchang, Derrick W. S. Chan et al. Review of clinical studies of perampanel in adolescent patients. Brain and Behavior. 2016; 6 (9): e00505.

23. Stephen L. J., Brodie M. J. Epilepsy in elderly people. Lancet. 2000; 355: 1441-6.

24. Trinka E., Steinhoff B. J., Nikanorova M. et al. Perampanel for focal epilepsy: insights from early clinical experience. Acta Neurol Scand. 2016; 133: 160-172.

25. Huberfeld G., Vecht C. J. Seizures and gliomas – towards a single therapeutic approach. Nat Rev Neurol. 2016; 12: 204-16.

26. Vecht et al. J Neurooncol. 2017; 133: 60-607.

27. Maschio et al. Poster p0232, IEC 2017.

28. Shershever et al. Poster p0239, IEC 2017.

29. Helmstaedter C., Witt J. The Neuropsychiatry of Epilepsy. 2011; 90-108.

30. Mula M., Sander J. W. Psychosocial aspects of epilepsy: a wider approach. BJPsych Open. 2016; 2: 270-274.

31. Schmitz B. Cognitive and behavioral outcome of epilepsy syndromes. Speakers` Presentations. Bologna. October 8-9th, 2004.

32. Villanueva V., Garcésa M., López-González F.J. et al. Safety, efficacy and outcomerelated factors of perampanel over 12months in a real-world setting: The FYDATA study. Epilepsy Research. 2016; 126: 201-210.

33. Jones R. M., Butler J. A., Thomas V. A. et al. Adherence to treatment in patients with epilepsy: associations with seizure conrol and illness beliefs. Seizure. 2006; 15L: 504-8.

34. WHO (World Health Organisation) (2003) Adherence to Long-Term Therapies: Evidence for Action. World Health Organisation, Geneva.

35. Gil-Nagel A., Burd S., Toledo M., Sander J. W., Lebedeva A., Patten A., Laurenza A. A retrospective, multicentre study of perampanel given as monotherapy in routine clinical care in people with epilepsy. Seizure. 2018; 54: 61-66.


For citation:


Resolution of the Expert Forum on the use of perampanel in routine clinical practice in Russia. Epilepsia and paroxyzmal conditions. 2018;10(3):71-78. (In Russ.)

Views: 40


ISSN 2077-8333 (Print)
ISSN 2311-4088 (Online)